Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
11 pending office actions • 7 clients • 10 examiners • 10 art units • 1 of 11 (9%) have an AI response strategy ready
MEDLEN & CARROLL, LLP focuses on Biotechnology & Pharmaceuticals and has handled 2,396 career applications. Its profile lists 12 pending office actions and a 72.87% resolved allowance rate.
Resolved matters have required an average of 4.36 office actions per allowance. The figures suggest that prosecution planning should allow for repeated examination responses, while the allowance rate provides a measure of the firm’s recorded resolution outcomes.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (9%) |
| §103 only | 2 (18%) |
| §102 only | 1 (9%) |
| §112 only | 1 (9%) |
| Double-patenting + other | 3 (27%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEONARD, ARTHUR S | 2 | 50.5% | +50.4% |
| BOWMAN, ANDREW J | 1 | 65.8% | +13.5% |
| NICONOVICH, ALEXANDER R | 1 | 72.7% | +21.7% |
| WASHINGTON, BRITNEY NICOLE | 1 | 84.0% | +13.2% |
| WARD, AARON DUREL | 1 | 0.0% | +0.0% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
| HOLLM, JONATHAN ADAM | 1 | 50.5% | +52.7% |
| PARENT, ALEXANDER RENE | 1 | 56.3% | +15.0% |
| LEE, JIA-HAI | 1 | 49.0% | +46.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | WASHINGTON, BRITNEY NICOLE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18670323 | FIGURE AND METHOD OF DECORATING A FIGURE | NICONOVICH, ALEXANDER R | — |
| 18577623 | MODULAR PRIME EDITING SYSTEMS FOR GENOME ENGINEERING | WARD, AARON DUREL | — |
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | KONOPKA, CATHERINE ANNE | — |
| 17608684 | CONVERSION OF CARBONATE INTO SYNGAS OR C2+ PRODUCTS IN ELECTROLYSIS CELL | PARENT, ALEXANDER RENE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18980456 | Targeted CRISPR Delivery Platforms | LEONARD, ARTHUR S | 50d overdue |
| 18199195 | SCAFFOLD LOADING AND DELIVERY SYSTEMS | HOLLM, JONATHAN ADAM | 19d overdue |
| 18810072 | IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS | BOWMAN, ANDREW J | 72d |
| 18670323 | FIGURE AND METHOD OF DECORATING A FIGURE | NICONOVICH, ALEXANDER R | — |
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | WASHINGTON, BRITNEY NICOLE | — |
| 18612111 | Targeted CRISPR Delivery Platforms | LEONARD, ARTHUR S | — |
| 18495089 | Novel Photocleavable Mass-Tags for Multiplexed Mass Spectrometric Imaging of Tissues Using Biomolecular Probes | PUTTLITZ, KARL J | — |
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | KONOPKA, CATHERINE ANNE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| UNIVERSITY OF MASSACHUSETTS | 4 |
| Lyra Therapeutics | 2 |
| Claymates LLC | 1 |
| EMULATE, Inc. | 1 |
| AmberGen, Inc. | 1 |
| THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO | 1 |
| Signablok, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1717 | 1 |
| 3711 | 1 |
| 1797 | 1 |
| 1636 | 1 |
| 1646 | 1 |
| 1635 | 1 |
| 3771 | 1 |
| 1700 | 1 |
| 1658 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18980456 | Targeted CRISPR Delivery Platforms | UNIVERSITY OF MASSACHUSETTS | LEONARD, ARTHUR S | 1631 | §112DP | Non-Final OA | 50d overdue | Pending | Dec 13, 2024 |
| 18810072 | IMPLANTABLE SCAFFOLDS FOR TREATMENT OF SINUSITIS | Lyra Therapeutics, Inc. | BOWMAN, ANDREW J | 1717 | §103 | Non-Final OA | 72d | Pending | Aug 20, 2024 |
| 18670323 | FIGURE AND METHOD OF DECORATING A FIGURE | Claymates LLC | NICONOVICH, ALEXANDER R | 3711 | §102§103§112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18659536 | ORGANS-ON-CHIPS AS A PLATFORM FOR EPIGENETICS DISCOVERY | Emulate, Inc. | WASHINGTON, BRITNEY NICOLE | 1797 | §102 | Non-Final OA | — | Pending | May 09, 2024 |
| 18612111 | Targeted CRISPR Delivery Platforms | UNIVERSITY OF MASSACHUSETTS | LEONARD, ARTHUR S | 1631 | §103§112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18577623 | MODULAR PRIME EDITING SYSTEMS FOR GENOME ENGINEERING | UNIVERSITY OF MASSACHUSETTS | WARD, AARON DUREL | 1636 | §102§112 | Non-Final OA | — | Pending | Jan 08, 2024 |
| 18495089 | Novel Photocleavable Mass-Tags for Multiplexed Mass Spectrometric Imaging of Tissues Using Biomolecular Probes | AmberGen, Inc. | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18553357 | Specific Oligonucleotide-Programmed Readthrough of Nonsense Codons | UNIVERSITY OF MASSACHUSETTS | KONOPKA, CATHERINE ANNE | 1635 | §101§102§112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18199195 | SCAFFOLD LOADING AND DELIVERY SYSTEMS | Lyra Therapeutics, Inc. | HOLLM, JONATHAN ADAM | 3771 | §103 | Non-Final OA | 19d overdue | Pending | May 18, 2023 |
| 17608684 | CONVERSION OF CARBONATE INTO SYNGAS OR C2+ PRODUCTS IN ELECTROLYSIS CELL | The Governing Council of the University of Toronto | PARENT, ALEXANDER RENE | 1700 | §102§103§112 | Non-Final OA | — | Pending | Nov 03, 2021 |
| 16719103 | Inhibition Of TCR Signaling With Peptide Variants | Signablok, Inc. | LEE, JIA-HAI | 1658 | §112 | Non-Final OA | — | AI Ready | Dec 18, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial72.9% of resolved applications prosecuted by Medlen & Carroll, LLP were allowed, across 2,396 applications in USPTO records.
4.36 office actions per allowed application on average.
11 pending office actions as of October 2026, for 7 clients, before 10 examiners in 10 art units.
